浩欧博收盘上涨2.26%，滚动市盈率214.27倍，总市值74.21亿元

Core Viewpoint - The company, Jiangsu Haobio Pharmaceutical Co., Ltd., is experiencing a decline in revenue and net profit, while its stock is trading at a significantly high price-to-earnings (PE) ratio compared to the industry average. Group 1: Company Performance - As of the latest report, the company achieved a revenue of 77.61 million yuan in Q1 2025, representing a year-on-year decrease of 9.33% [2] - The net profit for the same period was 1.64 million yuan, down 56.97% year-on-year, with a gross profit margin of 57.98% [2] - The company's stock closed at 116.9 yuan, with a PE ratio of 214.27, significantly higher than the industry average of 57.48 [1][3] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 57.48, with a median of 40.95, placing Haobio at the 115th position among its peers [1][3] - The company holds 12 institutional investors, all of which are funds, with a total holding of 1.1392 million shares valued at 15.5 million yuan [1]